Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model. Issue 144 (August 2016)

• Record Type: Journal Article
• Authors: Spavor, Maria; Halton, Jacqueline; Dietrich, Kevin; Israels, Sara; Shereck, Evan; Yong, Jian; Yasui, Yutaka; Mitchell, Lesley Gayle
• Is Part Of: Thrombosis research. Issue 144(2016)
• Page Start: 27
• Page End: 31
• Publication Date: 2016-08
• Subjects: Deep venous thrombosis -- Pediatrics -- Oncology -- Risk Factors; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2016.05.015
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Introduction: Pediatric oncology patients are at increased risk for deep venous thrombosis (DVT). Determining the sub-population of children at increased DVT risk is critical for optimum clinical management. Therefore, the aim of the current study was to identify clinical risk factors for DVT which are easily identifiable at cancer diagnosis. Materials and methods: A Canadian multicenter case control study in survivors of childhood cancer. Survivors who had DVT (Cases) while being treated for pediatric cancer where matched by center with a minimum of two survivors who did not experience DVT (Controls). Clinical information including age at diagnosis, type of cancer and chemotherapy were collected. Genotyping of blood group was done by single nucleotide polymorphisms analysis. Results: 218 subjects were recruited at 4 Canadian pediatric centers. Multivariable analysis demonstrated 3 significant variables (reported as Odds Ratio (OR), (95% CI), p value): age at diagnosis p < 0.001, non-O blood group OR 2.6 (1.3–5.2) p = 0.005 and asparaginase treatment OR 2.4 (1.2–4.8) p = 0.011. In order to optimise clinical utility, we reanalysed the study data with age at diagnosis categorised into four subgroups 0–≤ 2 years, > 2–≤ 7 years, > 7 ≤ 10 years, > 10 years. A significant association with DVT were seen in children 0- ≤ 2 years (OR 3.1 (1.1–8.3) p = 0.026) and > 10 years (OR 3.8, 1.7–8.5 p = 0.001). Significant associations with DVT remained for non-O blood group, OR 2.2 (1.2–4.4) p = 0.016 and asparaginase treatment, OR 2.1 (1.1–4.0) p = 0.027. The value for the clinical risk model receiver operating characteristics curve was 0.67. Conclusions: We have shown 3 independent risk factors for DVT in childhood cancer. Highlights: Multicenter study assessing clinical variables for DVT risk in children with cancer Multiple clinical variables were tested, 3 were independently associated with DVT. Age 0–≤ 2 or > 10 years at cancer diagnosis, non-O blood group, asparaginase treatment The presence of more than one variable in a patient multiplies DVT risk Variables can easily be determined at cancer diagnosis to identify at risk patients.